Social Media Ideas for Alz:ca

Canada’s Drug Agency recommends funding treatment for early-stage Alzheimer’s disease

Canada’s Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer’s disease if patients meet certain conditions...

Amyloidosis Continues To Fight Back

Add Alzheimer’s drug lecanemab to Canada’s public drug plans, agency says

Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease. 

ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE

A blood test for Alzheimer's disease biomarkers helped improve diagnostic accuracy among specialists and primary care physicians in a real-world study.In a head-to-head comparison...

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding

IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026

Spotting Alzheimer’s Early: Proactive Care Prevent Up to 40% of Dementia Cases

[The content of this article has been produced by our advertising partner.] As populations age and social stressors increase worldwide, cognitive health has become a pressing publi...

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

Tell HHS: Help Improve Alzheimer’s Health Outcomes

As the U.S. population continues to age, more Latinos and all people will face memory loss because of Alzheimer’s disease and related dementias.  Fortunately, every year, the U.S....

New smart technology can make diagnosis of Alzheimer’s disease more accessible

New Delhi, Aug 25: A novel smartphone-enabled platform employing afluorescence-responsive tiny molecule as a probe offers a simple, cost-effective, and accessible approach for the...

Letter: Create Medicare path to Alzheimer’s screening

I am a caregiver for my wife who was diagnosed with early-onset Alzheimer’s disease two years ago at age 56. We were fortunate that we were able to detect her illness early and dev...

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnti...

Double shrinkage transfer causal learning: An application to alzheimer’s disease

by Yunxin Shi, Lulu Pan, Yu Hu, Yongfu Yu, Guoyou Qin Amyloid-Beta 42 (ABeta42) is a key biomarker of cerebral amyloidosis in Alzheimer’s disease, and estimating its causal effect...

Trial Results for a PD-L1 Antibody Therapy to Reduce Inflammation in Alzheimer's Disease

Alzheimer's disease, and the other common age-related neurodegenerative conditions, are characterized by chronic inflammation in brain tissue. Aging in general is characterized by...

<![CDATA[Beyond Amyloid, Part Two (of two): Delivery, Diagnostics and the Path to Combination Care]]>

Alzheimer’s Research UK

www.alzheimersresearchuk.org Twitter: @ARUKnews Primary research areas Neurological Additional research areas Congenital disorders,  Ear,  Eye Grant types Early Career Fello...

Phase 1 Trial Validates Anti-PD-L1 Antibody for Alzheimer’s

IBC-Ab002, an anti-PD-L1 immunotherapy targeting systemic immune aging, is safe and reduces markers of neuronal damage in Alzheimer's patients.

A Newly Discovered Alzheimer’s Trigger Could Point to a Promising Treatment

A new ETH Zurich compound called Compound 10 blocks a misbehaving enzyme linked to Alzheimer's, slowing nerve cell death in mice. The post A Newly Discovered Alzheimer’s Trigger Co...

BRACE

www.alzheimers-brace.org LinkedIn: www.linkedin.com/company/brace---alzheimer's-research Primary research areas Neurological Grant types Lectureship/Professorship; Postgraduat...

Astera Labs, Inc. (ALAB) Q2 2026 Earnings Call Transcript

Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

<![CDATA[Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline]]>

BLOOD TEST MAY HELP PREDICT RISK OF COGNITIVE DECLINE DUE TO ALZHEIMER'S A DECADE BEFORE SYMPTOMS APPEAR

Key Takeaways

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline